Browse > Article

Overexpression of FGFR3 mRNA and Mutational Analysis of FGFR3 Gene in Hepatocellular Carcinoma  

Chang, Young Gyoon (Department of Pathology, College of Medicine, The Catholic University of Korea)
Bae, Hyun Jin (Department of Pathology, College of Medicine, The Catholic University of Korea)
Nam, Suk Woo (Department of Pathology, College of Medicine, The Catholic University of Korea)
Publication Information
YAKHAK HOEJI / v.56, no.6, 2012 , pp. 352-357 More about this Journal
Abstract
FGFR3 is a member of the fibroblast growth factor receptor family which interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Accumulated evidence suggests that aberrant regulation of FGFR3 and genetic alterations are implicated in the development and progression of various cancers. Despite a high incidence of FGFR3 over-expression, no such investigation has been performed in hepatocellular carcinoma. Thus, we investigated genetic alterations of the FGFR3 gene in 73 cases of hepatocellular carcinoma by single-strand conformational polymorphism (SSCP) and sequencing. One silent mutation (A369A) was found in the extracellular domain of FGFR3, and one genetic alteration in the immunoglobulin-like III domain of FGFR3 appeared to be polymorphism. Taken together, we concluded that over-expression of FGFR3 in hepatocellular carcinoma is not associated with genetic alterations of FGFR3 gene, and we suggest that there could be another underlying mechanism of aberrant FGFR3 expression in hepatocellular carcinoma.
Keywords
FGFR3; overexpression; mutation; hepatocellular carcinoma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Song, J., Kim, C. J., Cho, Y. G., Kim, S. Y., Nam, S. W., Lee, S. H., Yoo, N. J., Lee, J. Y. and Park, W. S. : Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 21, 1286 (2006).   DOI   ScienceOn
2 Villanueva, A., Newell, P., Chiang, D. Y., Friedman, S. L. and Llovet, J. M. : Genomics and signaling pathways in hepatocellular carcinoma. Seminars in Liver Disease. 27, 55 (2007).   DOI   ScienceOn
3 Sahadevan, K., Darby, S., Leung, H. Y., Mathers, M. E., Robson, C. N. and Gnanapragasam, V. J. : Selective overexpression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J. Pathol. 213, 82 (2007).   DOI   ScienceOn
4 Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. and Forman, D. : Global cancer statistics. CA Cancer J. Clin. 61, 69 (2011).   DOI
5 Whittaker, S., Marais, R. and Zhu, A. X. : The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 29, 4989 (2010).   DOI   ScienceOn
6 de La Coste, A., Romagnolo, B., Billuart, P., Renard, C. A., Buendia, M. A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A. and Perret, C. : Somatic mutations of the betacatenin gene are frequent in mouse and human hepatocellular carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 95, 8847 (1998).   DOI   ScienceOn
7 Pang, A., Ng, I. O., Fan, S. T. and Kwong, Y. L. : Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genetics and Cytogenetics 146, 8 (2003).   DOI   ScienceOn
8 Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., Yamaoka, Y. and Nakamura, Y. : AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virusmediated transfer of AXIN1. Nature Genetics. 24, 245 (2000).   DOI   ScienceOn
9 McKeehan, W. L., Wang, F. and Kan, M. : The heparan sulfatefibroblast growth factor family: diversity of structure and function. Prog. Nucleic. Acid Res. Mol. Biol. 59, 135 (1998).
10 Eswarakumar, V. P., Lax, I. and Schlessinger, J. : Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139 (2005).   DOI   ScienceOn
11 Hafner, C., Vogt, T. and Hartmann, A. : FGFR3 mutations in benign skin tumors. Cell Cycle. 5, 2723 (2006).   DOI   ScienceOn
12 Qiu, W. H., Zhou, B. S., Chu, P. G., Chen, W. G., Chung, C.,Shih, J., Hwu, P., Yeh, C., Lopez, R. and Yen, Y. : Overexpression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J. Gastroenterol. 11, 5266 (2005).   DOI
13 Kompier, L. C., Lurkin, I., van der Aa, M. N., van Rhijn, B. W., van der Kwast, T. H. and Zwarthoff, E. C. : FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 5, e13821 (2010).   DOI   ScienceOn
14 Bodoor, K., Ghabkari, A., Jaradat, Z., Alkhateeb, A., Jaradat, S., Al-Ghazo, M. A., Matalka, I., Musleh, H. and Haddad, Y. : FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 34, 724 (2010).   DOI   ScienceOn
15 Tomlinson, D. C., Hurst, C. D. and Knowles, M. A. : Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 26, 5889 (2007).   DOI   ScienceOn
16 Nam, S. W., Park, J. Y., Ramasamy, A., Shevade, S., Islam, A., Long, P. M., Park, C. K., Park, S. E., Kim, S. Y., Lee, S. H., Park, W. S., Yoo, N. J., Liu, E. T., Miller, L. D. and Lee, J. Y. : Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42, 809 (2005).   DOI   ScienceOn
17 Rousseau, F., el Ghouzzi, V., Delezoide, A. L., Legeai-Mallet, L., Le Merrer, M., Munnich, A. and Bonaventure, J. : Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet. 5, 509 (1996).   DOI   ScienceOn
18 Cao, K., Liu, W., Nakamura, H., Enomoto, H., Yamamoto, T., Saito, M., Imanishi, H., Shimomura, S., Cao, P. and Nishiguchi, S. : Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells. Hepatol Res. 39, 1108 (2009).   DOI   ScienceOn
19 Onwuazor, O. N., Wen, X. Y., Wang, D. Y., Zhuang, L., Masih- Khan, E., Claudio, J., Barlogie, B., Shaughnessy, J. D., Jr. and Stewart, A. K. : Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood. 102, 772 (2003).   DOI   ScienceOn
20 Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P. and Radvanyi, F. : Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 23, 18 (1999).
21 Sibley, K., Cuthbert-Heavens, D. and Knowles, M. A. : Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 20, 686 (2001).   DOI   ScienceOn
22 Tavormina, P. L., Rimoin, D. L., Cohn, D. H., Zhu, Y. Z., Shiang, R. and Wasmuth, J. J. : Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum Mol. Genet. 4, 2175 (1995).   DOI   ScienceOn
23 Winterpacht, A., Hilbert, K., Stelzer, C., Schweikardt, T., Decker, H., Segerer, H., Spranger, J. and Zabel, B. : A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol. Genomics. 2, 9 (2000).
24 Park, W. J., Bellus, G. A. and Jabs, E. W. : Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development. Am. J. Hum. Genet. 57, 748 (1995).
25 Hafner, C., van Oers, J. M., Vogt, T., Landthaler, M., Stoehr, R., Blaszyk, H., Hofstaedter, F., Zwarthoff, E. C. and Hartmann, A. : Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 116, 2201 (2006).   DOI   ScienceOn
26 Deutz-Terlouw, P. P., Losekoot, M., Aalfs, C. M., Hennekam, R. C. and Bakker, E. : Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia. Hum Mutat. Suppl 1, S62 (1998).
27 Superti-Furga, A., Eich, G., Bucher, H. U., Wisser, J., Giedion, A., Gitzelmann, R. and Steinmann, B. : A glycine 375-tocysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur. J. Pediatr. 154, 215 (1995).   DOI   ScienceOn
28 Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J. M., Maroteaux, P., Le Merrer, M. and Munnich, A. : Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252 (1994).   DOI   ScienceOn
29 Shiang, R., Thompson, L. M., Zhu, Y. Z., Church, D. M., Fielder, T. J., Bocian, M., Winokur, S. T. and Wasmuth, J. J. : Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 78, 335 (1994).   DOI   ScienceOn
30 Grigelioniene, G., Hagenas, L., Eklof, O., Neumeyer, L., Haereid, P. E. and Anvret, M. : A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online. Hum Mutat. 11, 333 (1998).
31 Mortier, G., Nuytinck, L., Craen, M., Renard, J. P., Leroy, J. G. and de Paepe, A. : Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene. J. Med. Genet. 37, 220 (2000).   DOI
32 Prinos, P., Costa, T., Sommer, A., Kilpatrick, M. W. and Tsipouras, P. : A common FGFR3 gene mutation in hypochondroplasia. Hum Mol Genet. 4, 2097 (1995).   DOI   ScienceOn
33 Rousseau, F., Saugier, P., Le Merrer, M., Munnich, A., Delezoide, A. L., Maroteaux, P., Bonaventure, J., Narcy, F. and Sanak, M. : Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat. Genet. 10, 11 (1995).   DOI   ScienceOn